Provided by Tiger Trade Technology Pte. Ltd.

Viking Therapeutics

34.17
+0.94002.83%
Post-market: 34.01-0.1600-0.47%17:43 EDT
Volume:2.10M
Turnover:71.87M
Market Cap:3.99B
PE:-7.32
High:34.99
Open:33.67
Low:33.43
Close:33.23
52wk High:43.15
52wk Low:22.96
Shares:116.65M
Float Shares:110.00M
Volume Ratio:1.19
T/O Rate:1.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.6676
EPS(LYR):-3.1920
ROE:-88.85%
ROA:-51.86%
PB:9.76
PE(LYR):-10.70

Loading ...

Der Aktionaer editor speculates on timing of Viking Therapeutics data

TIPRANKS
·
Yesterday

Viking Therapeutics (VKTX) Stock Still Looks Pricey With Pipeline Hopes Priced In

Simply Wall St.
·
Aug 20

Viking Therapeutics Director Dorothy Elizabeth Kelly-Gemmell Files Initial Beneficial Ownership Statement

Reuters
·
Aug 08

Viking Therapeutics Posts Corporate Presentation Outlining Obesity Drug Pipeline Led by Vk2735 Phase 3 Program

Reuters
·
Aug 06

Viking Therapeutics' VK2735 Drives Substantial Optionality, Oppenheimer Says

MT Newswires Live
·
Aug 04

Oppenheimer says VK2735’s options create compelling reason to own Viking

TIPRANKS
·
Aug 03

Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), AbbVie (ABBV) and Cencora (COR)

TIPRANKS
·
Aug 01

Tenax Therapeutics Q2 Net Loss Widens on Higher R&D Costs

Reuters
·
Jul 31

Viking's Obesity Treatments Advance as New Data, Trials Loom, Oppenheimer Says

MT Newswires Live
·
Jul 31

Viking Therapeutics is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Jul 31

Viking Therapeutics (VKTX) Receives a Buy from Jefferies

TIPRANKS
·
Jul 30

Truist Financial Sticks to Their Buy Rating for Viking Therapeutics (VKTX)

TIPRANKS
·
Jul 30

Madrigal Pharmaceuticals Q2 Revenue Rises 71% on Rezdiffra Demand

Reuters
·
Jul 30

Viking Therapeutics Inc Files for Mixed Shelf; Size not Disclosed - SEC Filing

THOMSON REUTERS
·
Jul 30

Viking Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 30

Viking Therapeutics Reports Q2 Milder-than-expected Net Loss as Obesity Trials Advance

Reuters
·
Jul 30

Viking Therapeutics reports Q2 EPS ($1.10) vs. (58c) last year

TIPRANKS
·
Jul 30

Viking Therapeutics Q2 EPS $(1.10) Beats $(1.25) Estimate

Benzinga Earnings
·
Jul 30

Viking Therapeutics Q2 EPS USD -1.1 Vs. IBES Estimate USD -1.25

Reuters
·
Jul 30

Viking Therapeutics (VKTX) Stock Looks Above Fair Value Today

Simply Wall St.
·
Jul 30